Search

312 results for "lecanemab".

Research summaries 283

Showing the best 200 of 283, 11–20, page 2 of 20. Filter these by subject, year and score in the research library →

1. Lecanemab Therapy Use Patterns for Alzheimer's Disease Among Early Initiators in a Large National Health PlanResearch summary

   Research summaries · alzhub.org/study/lecanemab-therapy-use-patterns-for-alzheimer-s-disease-among-early-41139687

   Lecanemab, an anti-amyloid monoclonal antibody, has been approved for treatment of early Alzheimer's disease. However, real-world data remain limited regarding use. Using data from a large national health plan with primarily …

2. Lecanemab and Vascular-Amyloid Deposition in Brains of People With Down SyndromeResearch summary

   Research summaries · alzhub.org/study/lecanemab-and-vascular-amyloid-deposition-in-brains-of-people-with-39158850

   Importance Anti-β-amyloid immunotherapy using lecanemab is becoming increasingly available to patients with Alzheimer disease (AD). Individuals with Down syndrome (DS) develop AD neuropathology by age 40 years, representing a …

3. Lecanemab appropriate use recommendations for clinical practice in the UKResearch summary

   Research summaries · alzhub.org/study/lecanemab-appropriate-use-recommendations-for-clinical-practice-in-41390238

   Lecanemab is an anti-amyloid monoclonal antibody, recently approved in the UK as a treatment for mild cognitive impairment (MCI) and mild dementia due to Alzheimer's disease (AD) in adults who are apolipoprotein E ε4 gene (APOE4) …

4. Lecanemab en la enfermedad de AlzheimerResearch summary

   Research summaries · alzhub.org/study/lecanemab-en-la-enfermedad-de-alzheimer-ab04d0ab

   … anticuerpos monoclonales, como lecanemab y donanemab, han mostrado su capacidad de eliminar, de forma rápida y sustancial, las placas cerebrales y han producido recientemente resultados cognitivos y clínicos alentadores en …

5. Lecanemab for early Alzheimer's disease: Appropriate use recommendations from the French federation of memory clinicsResearch summary

   Research summaries · alzhub.org/study/lecanemab-for-early-alzheimer-s-disease-appropriate-use-40011173

   Lecanemab, a monoclonal antibody targeting β-amyloid protofibrils, has shown promising results in a Phase III clinical trial for the treatment of early stages of Alzheimer's disease (AD) and has been approved by the European …

6. Lecanemab in patients with early Alzheimer's disease: detailed results on biomarker, cognitive, and clinical effects from the randomized and open-label extension of the phase 2 proof-of-concept studyResearch summary

   Research summaries · alzhub.org/study/lecanemab-in-patients-with-early-alzheimer-s-disease-detailed-results-36544184

   Background Lecanemab, a humanized IgG1 monoclonal antibody that targets soluble aggregated Aβ species (protofibrils), has demonstrated robust brain fibrillar amyloid reduction and slowing of clinical decline in early AD. The …

7. Lecanemab: A Humanized Monoclonal Antibody for the Treatment of Early Alzheimer DiseaseResearch summary

   Research summaries · alzhub.org/study/lecanemab-a-humanized-monoclonal-antibody-for-the-treatment-of-early-38095619

   … safety, and efficacy of lecanemab in patients with Alzheimer disease. Data sources A literature search of PubMed (April 1, 2016-November 15, 2023) and ClinicalTrials.gov search were conducted using the following search terms: …

8. Lecanemab: Appropriate Use RecommendationsResearch summary

   Research summaries · alzhub.org/study/lecanemab-appropriate-use-recommendations-37357276

   Lecanemab (Leqembi®) is approved in the United States for the treatment of Alzheimer's disease (AD) to be initiated in early AD (mild cognitive impairment [MCI] due to AD or mild AD dementia) with confirmed brain amyloid …

9. Lifetime cost-effectiveness of lecanemab for early Alzheimer's diseaseResearch summary

   Research summaries · alzhub.org/study/lifetime-cost-effectiveness-of-lecanemab-for-early-alzheimer-s-disease-41694525

   The incremental cost of the lecanemab group compared to the aducanumab group was $30,018.97, with an increase in quality-adjusted life-years (QALYs) of 0.25, resulting in an ICER of $121,678.49 per QALY gained. The result of the …

10. Long-term safety and efficacy of lecanemab in early Alzheimer's disease: Results from the Clarity AD open-label extension studyResearch summary

    Research summaries · alzhub.org/study/long-term-safety-and-efficacy-of-lecanemab-in-early-alzheimer-s-41355080

    Introduction In Clarity AD, lecanemab reduced markers of amyloid in early symptomatic Alzheimer's disease and slowed cognitive and functional decline at 18 months. Herein, we report 36-month data from the ongoing open-label …

How this search works

There is no outside search company involved. The site builds its own index by reading its own pages — the same words you would see on the page — and each result shows a literal snippet of that text with your words highlighted. Nothing is summarised or rewritten by a machine in between.

One addition, made by hand: a short list of everyday words that our pages cover under another name. Search "symptoms" and you are also shown The 10 warning signs; "medication" leads to Treatments & medicines; "hotline" to the helplines. A result reached that way shows the page's own description, and it only ever points to a page that already covers the subject.

27580 pages, questions, glossary terms and research summaries are indexed, last rebuilt 2026-11-03. Las páginas en español también aparecen en estos resultados. The clinical trial records are not in this index — they have their own finder, which searches all trial titles, sponsors and drugs directly.